SE8103003L - Terapeutisk forfarande for behandling av diabetes och farmaceutisk komposition for genomforande av forfarandet - Google Patents

Terapeutisk forfarande for behandling av diabetes och farmaceutisk komposition for genomforande av forfarandet

Info

Publication number
SE8103003L
SE8103003L SE8103003A SE8103003A SE8103003L SE 8103003 L SE8103003 L SE 8103003L SE 8103003 A SE8103003 A SE 8103003A SE 8103003 A SE8103003 A SE 8103003A SE 8103003 L SE8103003 L SE 8103003L
Authority
SE
Sweden
Prior art keywords
procedure
carnitine
implementation
pharmaceutical composition
treating diabetes
Prior art date
Application number
SE8103003A
Other languages
Unknown language ( )
English (en)
Inventor
C Cavazza
Original Assignee
Ind Farmaceutiche Riunite Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Farmaceutiche Riunite Spa filed Critical Ind Farmaceutiche Riunite Spa
Publication of SE8103003L publication Critical patent/SE8103003L/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE8103003A 1980-05-15 1981-05-13 Terapeutisk forfarande for behandling av diabetes och farmaceutisk komposition for genomforande av forfarandet SE8103003L (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT48692/80A IT1133010B (it) 1980-05-15 1980-05-15 Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo

Publications (1)

Publication Number Publication Date
SE8103003L true SE8103003L (sv) 1981-11-16

Family

ID=11268073

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8103003A SE8103003L (sv) 1980-05-15 1981-05-13 Terapeutisk forfarande for behandling av diabetes och farmaceutisk komposition for genomforande av forfarandet

Country Status (14)

Country Link
US (1) US4362719A (sv)
JP (1) JPS579721A (sv)
AU (1) AU540859B2 (sv)
BE (1) BE888797A (sv)
CA (1) CA1173749A (sv)
CH (1) CH654208A5 (sv)
DE (1) DE3119460A1 (sv)
FR (1) FR2482588B1 (sv)
GB (1) GB2075838B (sv)
IE (1) IE51224B1 (sv)
IL (1) IL62847A (sv)
IT (1) IT1133010B (sv)
NL (1) NL8102384A (sv)
SE (1) SE8103003L (sv)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
IT1237343B (it) * 1984-03-28 1993-05-31 Francia Farma Dicloridrato di acetildicarnitina, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) * 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
DE3635864A1 (de) * 1986-06-26 1988-05-05 Gerhard Gergely Verfahren zum herstellen eines brausegranulates, danach hergestelltes brausegranulat sowie dessen verwendung
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5420108A (en) * 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
MA26553A1 (fr) * 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
IT1306178B1 (it) * 1999-07-27 2001-05-30 Sigma Tau Ind Farmaceuti Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da
AU2002253857A1 (en) * 2001-01-08 2002-09-04 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
KR20100017460A (ko) * 2007-05-24 2010-02-16 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 피피에이알 감마 작용물질로 인한 부작용의 예방에 유용한 조성물
CN107121540B (zh) * 2016-02-24 2020-06-12 中国科学院上海营养与健康研究所 酰基肉碱谱或其检测试剂在2型糖尿病发病风险预测中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624887A (en) * 1970-03-02 1971-12-07 Bunker Ramo Pin and socket removal tool
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
JPS5058213A (sv) * 1973-09-26 1975-05-21
FR2414914A1 (fr) * 1978-01-18 1979-08-17 Sigma Tau Ind Farmaceuti Utilisations therapeutiques nouvelles de l'acetyl-1-carnitine et d'autres derives acyles de la 1-carnitine

Also Published As

Publication number Publication date
DE3119460A1 (de) 1982-03-04
IL62847A (en) 1985-01-31
JPS579721A (en) 1982-01-19
FR2482588A1 (fr) 1981-11-20
FR2482588B1 (fr) 1986-03-07
BE888797A (fr) 1981-08-28
CA1173749A (en) 1984-09-04
IE51224B1 (en) 1986-11-12
CH654208A5 (it) 1986-02-14
AU7048681A (en) 1981-11-26
GB2075838A (en) 1981-11-25
IT8048692A0 (it) 1980-05-15
US4362719A (en) 1982-12-07
NL8102384A (nl) 1981-12-01
GB2075838B (en) 1984-05-10
IT1133010B (it) 1986-07-09
IE811011L (en) 1981-11-15
IL62847A0 (en) 1981-07-31
AU540859B2 (en) 1984-12-06

Similar Documents

Publication Publication Date Title
SE8103003L (sv) Terapeutisk forfarande for behandling av diabetes och farmaceutisk komposition for genomforande av forfarandet
ES2258302T3 (es) Medicamento para el tratamiento de la diabetes mellitus asi como de sus efectos secundarios.
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
Crosby The rationale for treating iron deficiency anemia
KR880010764A (ko) 과콜레스테롤혈중 치료용 혼합물
NO842978L (no) Farmasoeytiske midler for behandling av diabetes
MX9203543A (es) Medicamento.
HUT50443A (en) Process for producing pharmaceutical composition suitable for treating diabetes mellitus
DE68911891D1 (de) Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung.
KR880013555A (ko) 당뇨병의 치료방법
DE3162614D1 (en) Dibenzoxazepine derivative, process for preparing the same and pharmaceutical composition comprising the same
JPS57126420A (en) Drug for digestive organ
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
ATE79749T1 (de) Verwendung von einigen alkanoyl-l-carnitinen zur herstellung eines arzneimittels zur therapeutischen behandlung von ideopathischem oder induziertem parkinsonismus.
KR920702225A (ko) 약학 조성물
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
US5114963A (en) Method of reducing serum levels of lipoprotein(A)
KR900700102A (ko) 심장질환 치료에 쓰이는 프로파페논과 퀴니딘의 지속성 조성물
SU606242A1 (ru) Антилепрозное средство "димоцифон"
RU96115219A (ru) Способ лечения больных сахарным диабетом
EE02938B1 (et) p-hüdroksübensoehappe derivaadid, nende valmistamismeetod ja kasutamine ravimitena
JPS5569510A (en) Carcinostatic agent
Friedman et al. Renal excretion of digitoxin as an indicator of (1) adequate and (2) excessive digitalization
Schottstaedt et al. Natural history and course of malignant hypertension
DE3777270D1 (de) Verwendung von l-carnitin zur herstellung eines arzneimittels zur behandlung von toxischen effekten, induziert durch die inhalation von halotan und anderen halogen enthaltenden allgemeinen anaesthetika.